Impulse Dynamics this week announced four new appointments to its executive team.
The company appointed Noel Colón as chief operating officer, Peter Donato as chief financial officer, Paul Bae as chief administrative officer and Anthony Hong as chief science and strategy officer.
“We are pleased to add these proven leaders to the Impulse Dynamics executive team – which now has more than 175 collective years of experience and success building commercial stage medical companies,” CEO Jason Spees said in a news release. “This team further strengthens the foundation for the next stage of the company, including strong future growth potential with the success of our proprietary CCM-D HF System – combining our proprietary CCM system (which improves the quality of life of heart failure patients) with an implantable defibrillator in a single device and procedure.”
More about the new executives
Colón has more than 30 years of experience in the medical device industry, including 15 years in various roles at Medtronic and 17 years in leadership roles spanning manufacturing, development, and quality at Boston Scientific.
Donato was more recently EVP and CFO of Zomedica before joining Impulse Dynamics. He also has more than 30 years of experience in the life sciences industry. Donato has held varying roles of responsibility at Standard Bariatrics, Neuronetics, Assurex Health, Bovie Medical, Iris International and Cyberonics.
Bae has decades of medtech leadership experience. He has worked for numerous companies, including Abbott, through its acquisition of St. Jude Medical. Most recently, he was chief legal officer at Canon Medical Systems USA.
Hong has more than three decades of experience in strategic planning in the pharmaceutical, biotech and medical device industries. He has experience using clinical evidence to support coverage, payment and inclusion in guidelines. Most recently, he was at Biosense Webster.
“We have chosen to invest in these leadership roles to drive innovation and evidence generation, elevate performance, and achieve key milestones as we strive to revolutionize the treatment of heart failure,” said Shlomi Nachman, chair of the board.
